Ospedale San Giovanni Bosco
- Address
- lock Available on a paid plan
Female Urogenital Diseases and Pregnancy Complications
At Ospedale San Giovanni Bosco, investigators are exploring how immune‑mediated kidney disorders such as IgG4‑Related Disease may influence women's reproductive health, with a focus on safety and disease control during pregnancy.
- Study of IgG4‑related disease in women of reproductive age
- Monitoring renal biomarkers throughout pregnancy
- Evaluating the safety profile of emerging biologics for maternal outcomes
The effort involves nine researchers from the SCdU Nefrologia e Dialisi- CMID department, underscoring the site’s dedication to integrating nephrology and obstetric care.
Immune System Diseases
Clinical research at the Turin hospital targets innovative treatments for rare immune conditions, aiming to lessen organ damage and improve quality of life for patients with Primary IgA Nephropathy and IgG4‑Related Disease.
- Obexelimab monoclonal antibody targeting IgG4 pathways
- Sefaxersen antisense inhibitor of complement factor B
- Proteinuria reduction as a therapeutic endpoint
Nine investigators collaborate to advance therapeutic options, reflecting the department’s commitment to cutting‑edge immune‑system research.
Male Urogenital Diseases
The research program also addresses the intersection of renal immune disorders and male urogenital health, evaluating how conditions like Primary IgA Nephropathy affect kidney function and related urological outcomes.
- Impact of IgA nephropathy on male renal outcomes
- Assessing novel treatments for proteinuria in men
- Integrating urological evaluation with nephrology trial protocols
Conducted by a team of nine specialists at SCdU Nefrologia e Dialisi- CMID, this work highlights the site’s holistic approach to male urogenital and kidney disease research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 59 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Chugai Pharmaceutical Co. Ltd.2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale San Giovanni Bosco
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 59 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alxn2220 | 1 | Unknown | 2024-04-30 | 2024-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.